Difference between revisions of "BRST5:Inflammatory myofibroblastic tumour"

From Compendium of Cancer Genome Aberrations
Jump to navigation Jump to search
VisualWikitext
[checked revision][checked revision]
Line 1: Line 1:
−
<span style="color:#0070C0">(''General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples). Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see'' </span><u>''[[Author_Instructions]]''</u><span style="color:#0070C0"> ''and [[Frequently Asked Questions (FAQs)|<u>FAQs</u>]] as well as contact your [[Leadership|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>])''</span>
 
−
 
 
==Primary Author(s)*==
 
==Primary Author(s)*==
  
−
Put your text here<span style="color:#0070C0"> (''Name and affiliation; example:'' Jane Smith, PhD, Institute of Genomics) </span>
+
Yajuan Liu, PhD, University of Washington
  
 
__TOC__
 
__TOC__
Line 9: Line 7:
 
==Cancer Category / Type==
 
==Cancer Category / Type==
  
−
Put your text here
+
Mesenchymal tumours of the breast
  
 
==Cancer Sub-Classification / Subtype==
 
==Cancer Sub-Classification / Subtype==
  
−
Put your text here
+
Fibroblastic and myofibroblastic tumors
  
 
==Definition / Description of Disease==
 
==Definition / Description of Disease==
Line 21: Line 19:
 
==Synonyms / Terminology==
 
==Synonyms / Terminology==
  
−
Put your text here <span style="color:#0070C0">(''Instructions: Include currently used terms and major historical ones, adding “(historical)” after the latter.'') </span>
+
Related terminology: inflammatory pseudotumour (historical, not recommended), inflammatory fibrosarcoma (historical, not recommended); plasma cell granuloma (historical, not recommended)  
  
 
==Epidemiology / Prevalence==
 
==Epidemiology / Prevalence==
  
−
Put your text here
+
Breast IMTs most often affect young to middle-aged females, although the age range is broad.<ref name=":0">{{Cite journal|last=Coffin|first=C. M.|last2=Watterson|first2=J.|last3=Priest|first3=J. R.|last4=Dehner|first4=L. P.|date=1995-08|title=Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases|url=https://pubmed.ncbi.nlm.nih.gov/7611533|journal=The American Journal of Surgical Pathology|volume=19|issue=8|pages=859–872|doi=10.1097/00000478-199508000-00001|issn=0147-5185|pmid=7611533}}</ref><ref>{{Cite journal|last=Makhlouf|first=Hala R.|last2=Sobin|first2=Leslie H.|date=2002-03|title=Inflammatory myofibroblastic tumors (inflammatory pseudotumors) of the gastrointestinal tract: how closely are they related to inflammatory fibroid polyps?|url=https://pubmed.ncbi.nlm.nih.gov/11979371|journal=Human Pathology|volume=33|issue=3|pages=307–315|doi=10.1053/hupa.2002.32213|issn=0046-8177|pmid=11979371}}</ref>
  
 
==Clinical Features==
 
==Clinical Features==
  
−
Put your text here and fill in the table <span style="color:#0070C0">(''Instruction: Can include references in the table'') </span>
+
Breast IMT usually presents as a painless, circumscribed mass.
 
{| class="wikitable"
 
{| class="wikitable"
 
|'''Signs and Symptoms'''
 
|'''Signs and Symptoms'''
Line 48: Line 46:
 
==Sites of Involvement==
 
==Sites of Involvement==
  
−
Put your text here <span style="color:#0070C0">(''Instruction: Indicate physical sites; Example: nodal, extranodal, bone marrow'') </span>
+
Breast IMT is rare and fewer than 25 reported cases.<ref>{{Cite journal|last=Khanafshar|first=Elham|last2=Phillipson|first2=Julia|last3=Schammel|first3=David P.|last4=Minobe|first4=Lorraine|last5=Cymerman|first5=Judith|last6=Weidner|first6=Noel|date=2005-06|title=Inflammatory myofibroblastic tumor of the breast|url=https://pubmed.ncbi.nlm.nih.gov/15944952|journal=Annals of Diagnostic Pathology|volume=9|issue=3|pages=123–129|doi=10.1016/j.anndiagpath.2005.02.001|issn=1092-9134|pmid=15944952}}</ref><ref>{{Cite journal|last=Haj|first=Mahmoud|last2=Weiss|first2=Michael|last3=Loberant|first3=Norman|last4=Cohen|first4=Isaac|date=2003|title=Inflammatory pseudotumor of the breast: case report and literature review|url=https://pubmed.ncbi.nlm.nih.gov/12968967|journal=The Breast Journal|volume=9|issue=5|pages=423–425|doi=10.1046/j.1524-4741.2003.09516.x|issn=1075-122X|pmid=12968967}}</ref><ref>{{Cite journal|last=Zhao|first=Hua-Dong|last2=Wu|first2=Tao|last3=Wang|first3=Jun-Qing|last4=Zhang|first4=Wen-Dong|last5=He|first5=Xian-Li|last6=Bao|first6=Guo-Qiang|last7=Li|first7=Yi|last8=Gong|first8=Li|last9=Wang|first9=Qing|date=2013-01|title=Primary inflammatory myofibroblastic tumor of the breast with rapid recurrence and metastasis: A case report|url=https://pubmed.ncbi.nlm.nih.gov/23255901|journal=Oncology Letters|volume=5|issue=1|pages=97–100|doi=10.3892/ol.2012.948|issn=1792-1074|pmc=3525499|pmid=23255901}}</ref><ref>{{Cite journal|last=Kovács|first=Anikó|last2=Máthé|first2=Gyöngyvér|last3=Mattsson|first3=Jan|last4=Stenman|first4=Göran|last5=Kindblom|first5=Lars-Gunnar|date=2015|title=ALK-Positive Inflammatory Myofibroblastic Tumor of the Nipple During Pregnancy-An Unusual Presentation of a Rare Disease|url=https://pubmed.ncbi.nlm.nih.gov/25772857|journal=The Breast Journal|volume=21|issue=3|pages=297–302|doi=10.1111/tbj.12404|issn=1524-4741|pmid=25772857}}</ref> IMT shows a wide anatomical distribution, most frequently arising in the respiratory tract, abdominal cavity, and retroperitoneum, followed by the lung, mediastinum, head and neck, gastrointestinal tract, and genitourinary tract (including the bladder and uterus).<ref name=":0" /><ref name=":1">{{Cite journal|last=Gleason|first=B. C.|last2=Hornick|first2=J. L.|date=2008-04|title=Inflammatory myofibroblastic tumours: where are we now?|url=https://pubmed.ncbi.nlm.nih.gov/17938159|journal=Journal of Clinical Pathology|volume=61|issue=4|pages=428–437|doi=10.1136/jcp.2007.049387|issn=1472-4146|pmid=17938159}}</ref><ref>{{Cite journal|last=Karnak|first=I.|last2=Senocak|first2=M. E.|last3=Ciftci|first3=A. O.|last4=Cağlar|first4=M.|last5=Bingöl-Koloğlu|first5=M.|last6=Tanyel|first6=F. C.|last7=Büyükpamukçu|first7=N.|date=2001-06|title=Inflammatory myofibroblastic tumor in children: diagnosis and treatment|url=https://pubmed.ncbi.nlm.nih.gov/11381424|journal=Journal of Pediatric Surgery|volume=36|issue=6|pages=908–912|doi=10.1053/jpsu.2001.23970|issn=0022-3468|pmid=11381424}}</ref><ref>{{Cite journal|last=Tsuzuki|first=Toyonori|last2=Magi-Galluzzi|first2=Cristina|last3=Epstein|first3=Jonathan I.|date=2004-12|title=ALK-1 expression in inflammatory myofibroblastic tumor of the urinary bladder|url=https://pubmed.ncbi.nlm.nih.gov/15577680|journal=The American Journal of Surgical Pathology|volume=28|issue=12|pages=1609–1614|doi=10.1097/00000478-200412000-00009|issn=0147-5185|pmid=15577680}}</ref> Unusual locations include somatic soft tissues, pancreas, liver, and CNS.<ref name=":0" /><ref name=":1" /><ref>{{Cite journal|last=Ramachandra|first=S.|last2=Hollowood|first2=K.|last3=Bisceglia|first3=M.|last4=Fletcher|first4=C. D.|date=1995-10|title=Inflammatory pseudotumour of soft tissues: a clinicopathological and immunohistochemical analysis of 18 cases|url=https://pubmed.ncbi.nlm.nih.gov/8847061|journal=Histopathology|volume=27|issue=4|pages=313–323|doi=10.1111/j.1365-2559.1995.tb01521.x|issn=0309-0167|pmid=8847061}}</ref>
  
 
==Morphologic Features==
 
==Morphologic Features==
  
−
Put your text here
+
Most tumors are < 5 cm in size, with white to grey and sometimes yellow cut surfaces.
 +
 
 +
Loose fascicles of uniform, plump spindle cells with vesicular chromatin, small nucleoli, and pale eosinophilic to amphophilic cytoplasm are typically observed. <ref name=":0" /> The stroma may be myxoid or collagenous, usually containing an inflammatory infiltrate dominated by lymphocytes and plasma cells, with fewer eosinophils and neutrophils. Some tumours exhibit a compact, fascicular architecture with minimal stroma. A subset of tumour cells may resemble ganglion cells. Mitotic activity is low and necrosis is usually absent.
  
 
==Immunophenotype==
 
==Immunophenotype==
  
−
Put your text here and fill in the table <span style="color:#0070C0">(''Instruction: Can include references in the table'') </span>
+
Essential and desirable diagnostic criteria include loose fascicles of plump spindle cells without substantial atypia or pleomorphism; inflammatory infiltrate of lymphocytes and plasma cells; consistent SMA expression; frequent ALK expression.
  
 
{| class="wikitable sortable"
 
{| class="wikitable sortable"
Line 62: Line 62:
 
!Finding!!Marker
 
!Finding!!Marker
 
|-
 
|-
−
|Positive (universal)||EXAMPLE CD1
+
|Positive (universal)||SMA
 
|-
 
|-
−
|Positive (subset)||EXAMPLE CD2
+
|Positive (subset)||desmin, ALK (~60%),<ref name=":2">{{Cite journal|last=Cook|first=J. R.|last2=Dehner|first2=L. P.|last3=Collins|first3=M. H.|last4=Ma|first4=Z.|last5=Morris|first5=S. W.|last6=Coffin|first6=C. M.|last7=Hill|first7=D. A.|date=2001-11|title=Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study|url=https://pubmed.ncbi.nlm.nih.gov/11684952|journal=The American Journal of Surgical Pathology|volume=25|issue=11|pages=1364–1371|doi=10.1097/00000478-200111000-00003|issn=0147-5185|pmid=11684952}}</ref><ref name=":3">{{Cite journal|last=Pickett|first=Justine L.|last2=Chou|first2=Angela|last3=Andrici|first3=Juliana A.|last4=Clarkson|first4=Adele|last5=Sioson|first5=Loretta|last6=Sheen|first6=Amy|last7=Reagh|first7=Jessica|last8=Najdawi|first8=Fedaa|last9=Kim|first9=Yoomee|date=2017-10|title=Inflammatory Myofibroblastic Tumors of the Female Genital Tract Are Under-recognized: A Low Threshold for ALK Immunohistochemistry Is Required|url=https://pubmed.ncbi.nlm.nih.gov/28731868|journal=The American Journal of Surgical Pathology|volume=41|issue=10|pages=1433–1442|doi=10.1097/PAS.0000000000000909|issn=1532-0979|pmc=5598906|pmid=28731868}}</ref> ROS1 (~5%)<ref name=":4">{{Cite journal|last=Hornick|first=Jason L.|last2=Sholl|first2=Lynette M.|last3=Dal Cin|first3=Paola|last4=Childress|first4=Merrida A.|last5=Lovly|first5=Christine M.|date=2015-05|title=Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors|url=https://pubmed.ncbi.nlm.nih.gov/25612511|journal=Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc|volume=28|issue=5|pages=732–739|doi=10.1038/modpathol.2014.165|issn=1530-0285|pmc=5874150|pmid=25612511}}</ref> <ref name=":5">{{Cite journal|last=Antonescu|first=Cristina R.|last2=Suurmeijer|first2=Albert J. H.|last3=Zhang|first3=Lei|last4=Sung|first4=Yun-Shao|last5=Jungbluth|first5=Achim A.|last6=Travis|first6=William D.|last7=Al-Ahmadie|first7=Hikmat|last8=Fletcher|first8=Christopher D. M.|last9=Alaggio|first9=Rita|date=2015-07|title=Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement|url=https://pubmed.ncbi.nlm.nih.gov/25723109|journal=The American Journal of Surgical Pathology|volume=39|issue=7|pages=957–967|doi=10.1097/PAS.0000000000000404|issn=1532-0979|pmc=4465992|pmid=25723109}}</ref>
 
|-
 
|-
−
|Negative (universal)||EXAMPLE CD3
+
|Negative (universal)||keratin
 
|-
 
|-
−
|Negative (subset)||EXAMPLE CD4
+
|Negative (subset)||CD34, S100, SOX10, and EMA
 
|}
 
|}
  
 
==Chromosomal Rearrangements (Gene Fusions)==
 
==Chromosomal Rearrangements (Gene Fusions)==
  
−
Put your text here and fill in the table
+
Confirmation of ALK or other gene rearrangements supports the diagnosis. However, molecular confirmation is not required if ALK immunohistochemistry is definitively positive.<ref name=":6">{{Cite journal|last=Coffin|first=C. M.|last2=Patel|first2=A.|last3=Perkins|first3=S.|last4=Elenitoba-Johnson|first4=K. S.|last5=Perlman|first5=E.|last6=Griffin|first6=C. A.|date=2001-06|title=ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor|url=https://pubmed.ncbi.nlm.nih.gov/11406658|journal=Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc|volume=14|issue=6|pages=569–576|doi=10.1038/modpathol.3880352|issn=0893-3952|pmid=11406658}}</ref> Of note, exceptional situations such as inversion of ALK on the same chromosome arm may lead to a false-negative FISH result. <ref>{{Cite journal|last=Haimes|first=Josh D.|last2=Stewart|first2=Colin J. R.|last3=Kudlow|first3=Brian A.|last4=Culver|first4=Brady P.|last5=Meng|first5=Bo|last6=Koay|first6=Eleanor|last7=Whitehouse|first7=Ann|last8=Cope|first8=Nichola|last9=Lee|first9=Jen-Chieh|date=2017-06|title=Uterine Inflammatory Myofibroblastic Tumors Frequently Harbor ALK Fusions With IGFBP5 and THBS1|url=https://pubmed.ncbi.nlm.nih.gov/28490045|journal=The American Journal of Surgical Pathology|volume=41|issue=6|pages=773–780|doi=10.1097/PAS.0000000000000801|issn=1532-0979|pmid=28490045}}</ref>, and other molecular testing such as RNA-Seq can be used to detect ALK fusions efficiently. In ALK-negative cases, immunohistochemistry for ROS1 and/or molecular tests for non-ALK gene fusions (e.g. NTRK3) may be useful.<ref name=":7">{{Cite journal|last=Yamamoto|first=Hidetaka|last2=Yoshida|first2=Akihiko|last3=Taguchi|first3=Kenichi|last4=Kohashi|first4=Kenichi|last5=Hatanaka|first5=Yui|last6=Yamashita|first6=Atsushi|last7=Mori|first7=Daisuke|last8=Oda|first8=Yoshinao|date=2016-07|title=ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours|url=https://pubmed.ncbi.nlm.nih.gov/26647767|journal=Histopathology|volume=69|issue=1|pages=72–83|doi=10.1111/his.12910|issn=1365-2559|pmid=26647767}}</ref><ref name=":8">{{Cite journal|last=Lovly|first=Christine M.|last2=Gupta|first2=Abha|last3=Lipson|first3=Doron|last4=Otto|first4=Geoff|last5=Brennan|first5=Tina|last6=Chung|first6=Catherine T.|last7=Borinstein|first7=Scott C.|last8=Ross|first8=Jeffrey S.|last9=Stephens|first9=Philip J.|date=2014-08|title=Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions|url=https://pubmed.ncbi.nlm.nih.gov/24875859|journal=Cancer Discovery|volume=4|issue=8|pages=889–895|doi=10.1158/2159-8290.CD-14-0377|issn=2159-8290|pmc=4125481|pmid=24875859}}</ref><ref name=":9">{{Cite journal|last=Alassiri|first=Ali H.|last2=Ali|first2=Rola H.|last3=Shen|first3=Yaoqing|last4=Lum|first4=Amy|last5=Strahlendorf|first5=Caron|last6=Deyell|first6=Rebecca|last7=Rassekh|first7=Rod|last8=Sorensen|first8=Poul H.|last9=Laskin|first9=Janessa|date=2016-08|title=ETV6-NTRK3 Is Expressed in a Subset of ALK-Negative Inflammatory Myofibroblastic Tumors|url=https://pubmed.ncbi.nlm.nih.gov/27259007|journal=The American Journal of Surgical Pathology|volume=40|issue=8|pages=1051–1061|doi=10.1097/PAS.0000000000000677|issn=1532-0979|pmid=27259007}}</ref><ref name=":5" />
  
 
{| class="wikitable sortable"
 
{| class="wikitable sortable"
Line 83: Line 83:
 
!Notes
 
!Notes
 
|-
 
|-
−
|EXAMPLE t(9;22)(q34;q11.2)||EXAMPLE 3'ABL1 / 5'BCR||EXAMPLE der(22)||EXAMPLE 20% (COSMIC)
+
|t(2;var)(p23;var)||5'var::3'''ALK''
−
EXAMPLE 30% (add reference)
+
(various 5’partner genes include ''TPM3'', ''TPM4'', ''CLTC'', ''CARS'', ''ATIC'', ''SEC31L1'', ''PPFIBP1'', ''DCTN1'', ''EML4'', ''PRKAR1A'', ''LMNA'', ''TFG'', ''FN1'', ''HNRNPA1'', etc)
 +
|der(var)||50-60%<ref name=":10">{{Cite journal|last=Bridge|first=J. A.|last2=Kanamori|first2=M.|last3=Ma|first3=Z.|last4=Pickering|first4=D.|last5=Hill|first5=D. A.|last6=Lydiatt|first6=W.|last7=Lui|first7=M. Y.|last8=Colleoni|first8=G. W.|last9=Antonescu|first9=C. R.|date=2001-08|title=Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor|url=https://pubmed.ncbi.nlm.nih.gov/11485898|journal=The American Journal of Pathology|volume=159|issue=2|pages=411–415|doi=10.1016/S0002-9440(10)61711-7|issn=0002-9440|pmc=1850566|pmid=11485898}}</ref><ref>{{Cite journal|last=Chen|first=Sung-Ting|last2=Lee|first2=Jen-Chieh|date=2008-12|title=An inflammatory myofibroblastic tumor in liver with ALK and RANBP2 gene rearrangement: combination of distinct morphologic, immunohistochemical, and genetic features|url=https://pubmed.ncbi.nlm.nih.gov/18701132|journal=Human Pathology|volume=39|issue=12|pages=1854–1858|doi=10.1016/j.humpath.2008.04.016|issn=1532-8392|pmid=18701132}}</ref><ref>{{Cite journal|last=Debelenko|first=Larisa V.|last2=Arthur|first2=Diane C.|last3=Pack|first3=Svetlana D.|last4=Helman|first4=Lee J.|last5=Schrump|first5=David S.|last6=Tsokos|first6=Maria|date=2003-09|title=Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor|url=https://pubmed.ncbi.nlm.nih.gov/13679433|journal=Laboratory Investigation; a Journal of Technical Methods and Pathology|volume=83|issue=9|pages=1255–1265|doi=10.1097/01.lab.0000088856.49388.ea|issn=0023-6837|pmid=13679433}}</ref><ref>{{Cite journal|last=Griffin|first=C. A.|last2=Hawkins|first2=A. L.|last3=Dvorak|first3=C.|last4=Henkle|first4=C.|last5=Ellingham|first5=T.|last6=Perlman|first6=E. J.|date=1999-06-15|title=Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors|url=https://pubmed.ncbi.nlm.nih.gov/10383129|journal=Cancer Research|volume=59|issue=12|pages=2776–2780|issn=0008-5472|pmid=10383129}}</ref><ref>{{Cite journal|last=Lawrence|first=B.|last2=Perez-Atayde|first2=A.|last3=Hibbard|first3=M. K.|last4=Rubin|first4=B. P.|last5=Dal Cin|first5=P.|last6=Pinkus|first6=J. L.|last7=Pinkus|first7=G. S.|last8=Xiao|first8=S.|last9=Yi|first9=E. S.|date=2000-08|title=TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors|url=https://pubmed.ncbi.nlm.nih.gov/10934142|journal=The American Journal of Pathology|volume=157|issue=2|pages=377–384|doi=10.1016/S0002-9440(10)64550-6|issn=0002-9440|pmc=1850130|pmid=10934142}}</ref><ref>{{Cite journal|last=Takeuchi|first=Kengo|last2=Soda|first2=Manabu|last3=Togashi|first3=Yuki|last4=Sugawara|first4=Emiko|last5=Hatano|first5=Satoko|last6=Asaka|first6=Reimi|last7=Okumura|first7=Sakae|last8=Nakagawa|first8=Ken|last9=Mano|first9=Hiroyuki|date=2011-05-15|title=Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK: reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification|url=https://pubmed.ncbi.nlm.nih.gov/21430068|journal=Clinical Cancer Research: An Official Journal of the American Association for Cancer Research|volume=17|issue=10|pages=3341–3348|doi=10.1158/1078-0432.CCR-11-0063|issn=1557-3265|pmid=21430068}}</ref><ref>{{Cite journal|last=Yamamoto|first=Hidetaka|last2=Kohashi|first2=Kenichi|last3=Oda|first3=Yoshinao|last4=Tamiya|first4=Sadafumi|last5=Takahashi|first5=Yukiko|last6=Kinoshita|first6=Yoshiaki|last7=Ishizawa|first7=Shin|last8=Kubota|first8=Masayuki|last9=Tsuneyoshi|first9=Masazumi|date=2006-10|title=Absence of human herpesvirus-8 and Epstein-Barr virus in inflammatory myofibroblastic tumor with anaplastic large cell lymphoma kinase fusion gene|url=https://pubmed.ncbi.nlm.nih.gov/16984614|journal=Pathology International|volume=56|issue=10|pages=584–590|doi=10.1111/j.1440-1827.2006.02012.x|issn=1320-5463|pmid=16984614}}</ref><ref>{{Cite journal|last=Inamura|first=Kentaro|last2=Kobayashi|first2=Maki|last3=Nagano|first3=Hiroko|last4=Sugiura|first4=Yoshiya|last5=Ogawa|first5=Masahiro|last6=Masuda|first6=Hitoshi|last7=Yonese|first7=Junji|last8=Ishikawa|first8=Yuichi|date=2017-11|title=A novel fusion of HNRNPA1-ALK in inflammatory myofibroblastic tumor of urinary bladder|url=https://pubmed.ncbi.nlm.nih.gov/28504207|journal=Human Pathology|volume=69|pages=96–100|doi=10.1016/j.humpath.2017.04.022|issn=1532-8392|pmid=28504207}}</ref><ref name=":8" />
 
|Yes
 
|Yes
 +
|Yes (ALK-negative IMTs may have a higher likelihood of metastasis)
 +
|Yes
 +
|IMT with ALK genomic rearrangement features activation and overexpression of the ALK C-terminal kinase region, which is restricted to the neoplastic myofibroblastic component <ref name=":10" /><ref name=":6" /><ref name=":2" />
 +
|-
 +
|t(3;6)(q12.2;q22.1), t(6;17)(q22.1;p13.3)
 +
|''TFG''::''ROS1'', ''YWHAE''::''ROS1''
 +
|der(var)
 +
|5-10%<ref name=":8" /><ref name=":4" /><ref name=":9" /><ref name=":5" /><ref name=":7" />
 +
|Yes
 +
|No
 +
|Yes
 +
|
 +
|-
 +
|t(12;15)(p13.2;q25.3)
 +
|''ETV6''::''NTRK3''
 +
|der(15)
 +
|>5%<ref name=":8" /><ref name=":5" />
 +
|Yes
 +
|No
 +
|Yes
 +
|Therapy options for NTRK fusions include Larotrectinib and Entrectinib (clinically approved)
 +
|-
 +
|t(5;12)(q32;q13.3)
 +
|NAB2::PDGFRB
 +
|der(5)
 +
|>1%<ref name=":8" />
 +
|Unknown
 +
|No
 +
|Yes
 +
|
 +
|-
 +
|rea(10q11.21)
 +
|rea(RET)
 +
|der(10)
 +
|>1%<ref name=":5" />
 +
|Unknown
 
|No
 
|No
 
|Yes
 
|Yes
−
|EXAMPLE
+
|Detected by FISH break-apart probe
−
 
 
−
The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference).
 
 
|}
 
|}
 
 
 
==Individual Region Genomic Gain / Loss / LOH==
 
==Individual Region Genomic Gain / Loss / LOH==
  
−
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'') </span>
+
NA
  
 
{| class="wikitable sortable"
 
{| class="wikitable sortable"
Line 105: Line 140:
 
!Notes
 
!Notes
 
|-
 
|-
−
|EXAMPLE
+
|NA
−
 
+
|NA
−
7
+
|
−
|EXAMPLE Loss
+
|
−
|EXAMPLE
+
|
−
 
+
|
−
chr7:1- 159,335,973 [hg38]
+
|
−
|EXAMPLE
+
|
−
 
 
−
chr7
 
−
|Yes
 
−
|Yes
 
−
|No
 
−
|EXAMPLE
 
−
 
 
−
Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference).  Monosomy 7/7q deletion is associated with a poor prognosis in AML (add reference).
 
 
|-
 
|-
−
|EXAMPLE
+
|NA
−
 
+
|NA
−
8
+
|
−
|EXAMPLE Gain
+
|
−
|EXAMPLE
+
|
−
 
+
|
−
chr8:1-145,138,636 [hg38]
+
|
−
|EXAMPLE
+
|.
−
 
 
−
chr8
 
−
|No
 
−
|No
 
−
|No
 
−
|EXAMPLE
 
−
 
 
−
Common recurrent secondary finding for t(8;21) (add reference).
 
 
|}
 
|}
 
==Characteristic Chromosomal Patterns==
 
==Characteristic Chromosomal Patterns==
  
−
Put your text here <span style="color:#0070C0">(''EXAMPLE PATTERNS: hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis'')</span>
+
NA
  
 
{| class="wikitable sortable"
 
{| class="wikitable sortable"
Line 151: Line 170:
 
!Notes
 
!Notes
 
|-
 
|-
−
|EXAMPLE
+
|NA
−
 
+
|
−
Co-deletion of 1p and 18q
+
|
−
|Yes
+
|
−
|No
+
|
−
|No
 
−
|EXAMPLE:
 
−
 
 
−
See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference).
 
 
|}
 
|}
 
==Gene Mutations (SNV / INDEL)==
 
==Gene Mutations (SNV / INDEL)==
  
−
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.'') </span>
+
NA
  
 
{| class="wikitable sortable"
 
{| class="wikitable sortable"
Line 173: Line 188:
 
!Notes
 
!Notes
 
|-
 
|-
−
|EXAMPLE: TP53; Variable LOF mutations
+
|NA
−
 
+
|
−
EXAMPLE:
+
|
−
 
+
|
−
EGFR; Exon 20 mutations
+
|
−
 
+
|
−
EXAMPLE: BRAF; Activating mutations
 
−
|EXAMPLE: TSG
 
−
|EXAMPLE: 20% (COSMIC)
 
−
 
 
−
EXAMPLE: 30% (add Reference)
 
−
|EXAMPLE: IDH1 R123H
 
−
|EXAMPLE: EGFR amplification
 
 
|
 
|
 
|
 
|
 
|
 
|
−
|EXAMPLE:  Excludes hairy cell leukemia (HCL) (add reference).
 
−
<br />
 
 
|}
 
|}
 
Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.
 
Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.
Line 196: Line 202:
 
==Epigenomic Alterations==
 
==Epigenomic Alterations==
  
−
Put your text here
+
NA
  
 
==Genes and Main Pathways Involved==
 
==Genes and Main Pathways Involved==
  
−
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Can include references in the table.'')</span>
+
IMTs are genetically heterogeneous. About two thirds of inflammatory myofibroblastic tumours harbour receptor tyrosine kinase gene rearrangements, most often involving the ''ALK'' locus at 2p23, with diverse fusion partners. <ref>{{Cite journal|last=Mariño-Enríquez|first=Adrian|last2=Dal Cin|first2=Paola|date=2013-11|title=ALK as a paradigm of oncogenic promiscuity: different mechanisms of activation and different fusion partners drive tumors of different lineages|url=https://pubmed.ncbi.nlm.nih.gov/24091028|journal=Cancer Genetics|volume=206|issue=11|pages=357–373|doi=10.1016/j.cancergen.2013.07.001|issn=2210-7762|pmid=24091028}}</ref> Approximately 5% of inflammatory myofibroblastic tumours harbour ''ROS1'' gene fusions; other rare gene fusions involve ''NTRK3'', ''PDGFRB'', and ''RET.'' <ref name=":8" /><ref name=":5" /><ref name=":7" /><ref name=":9" /><ref name=":3" />
 
{| class="wikitable sortable"
 
{| class="wikitable sortable"
 
|-
 
|-
 
!Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome
 
!Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome
 
|-
 
|-
−
|EXAMPLE: BRAF and MAP2K1; Activating mutations
+
|''ALK'' fusion; activating rearrangement
−
|EXAMPLE: MAPK signaling
+
|Kinase fusions, receptor tyrosine kinase/growth factor signaling
−
|EXAMPLE: Increased cell growth and proliferation
+
|uncontrolled cell proliferation and survival
 +
|-
 +
|''ROS1'' fusion; activating rearrangement
 +
|Kinase fusions, receptor tyrosine kinase/growth factor signaling
 +
|cell growth and differentiation
 +
|-
 +
|''NTRK3'' fusion; activating rearrangement
 +
|Kinase fusions, receptor tyrosine kinase/growth factor signaling
 +
|cell differentiation
 
|-
 
|-
−
|EXAMPLE: CDKN2A; Inactivating mutations
+
|''PDGFRB'' fusion; activating rearrangement
−
|EXAMPLE: Cell cycle regulation
+
|Kinase fusions, receptor tyrosine kinase/growth factor signaling
−
|EXAMPLE: Unregulated cell division
+
|cell growth
 
|-
 
|-
−
|EXAMPLE:  KMT2C and ARID1A; Inactivating mutations
+
|''RET'' fusion; activating rearrangement
−
|EXAMPLE:  Histone modification, chromatin remodeling
+
|Kinase fusions, receptor tyrosine kinase/growth factor signaling
−
|EXAMPLE:  Abnormal gene expression program
+
|cell growth
 
|}
 
|}
 
==Genetic Diagnostic Testing Methods==
 
==Genetic Diagnostic Testing Methods==
  
−
Put your text here
+
FISH, RT-PCR, RNA-seq
  
 
==Familial Forms==
 
==Familial Forms==
  
−
Put your text here <span style="color:#0070C0">(''Instructions: Include associated hereditary conditions/syndromes that cause this entity or are caused by this entity.'') </span>
+
<br />
  
 
==Additional Information==
 
==Additional Information==
  
−
Put your text here
+
<br />
  
 
==Links==
 
==Links==
  
−
Put your text placeholder here (or anywhere appropriate on the page) and use the "Link" icon at the top of the page <span style="color:#0070C0">(''Instructions: Once you have a text placeholder entered to which you want to add a link, highlight that text, select the "Link" icon at the top of the page, and search the name of the internal page to which you want to link this text, or enter an external internet address including the "<nowiki>http://www</nowiki>." portion.'')</span>
+
<br />
  
 
==References==
 
==References==

Revision as of 09:49, 7 December 2023

Primary Author(s)*

Yajuan Liu, PhD, University of Washington

Cancer Category / Type

Mesenchymal tumours of the breast

Cancer Sub-Classification / Subtype

Fibroblastic and myofibroblastic tumors

Definition / Description of Disease

Put your text here (Instructions: Brief description of approximately one paragraph - include disease context relative to other WHO classification categories referring to the specific WHO book pages, diagnostic criteria if applicable, and differential diagnosis if applicable)

Synonyms / Terminology

Related terminology: inflammatory pseudotumour (historical, not recommended), inflammatory fibrosarcoma (historical, not recommended); plasma cell granuloma (historical, not recommended)

Epidemiology / Prevalence

Breast IMTs most often affect young to middle-aged females, although the age range is broad.[1][2]

Clinical Features

Breast IMT usually presents as a painless, circumscribed mass.

Signs and Symptoms EXAMPLE Asymptomatic (incidental finding on complete blood counts)

EXAMPLE B-symptoms (weight loss, fever, night sweats)

EXAMPLE Fatigue

EXAMPLE Lymphadenopathy (uncommon)

Laboratory Findings EXAMPLE Cytopenias

EXAMPLE Lymphocytosis (low level)

Sites of Involvement

Breast IMT is rare and fewer than 25 reported cases.[3][4][5][6] IMT shows a wide anatomical distribution, most frequently arising in the respiratory tract, abdominal cavity, and retroperitoneum, followed by the lung, mediastinum, head and neck, gastrointestinal tract, and genitourinary tract (including the bladder and uterus).[1][7][8][9] Unusual locations include somatic soft tissues, pancreas, liver, and CNS.[1][7][10]

Morphologic Features

Most tumors are < 5 cm in size, with white to grey and sometimes yellow cut surfaces.

Loose fascicles of uniform, plump spindle cells with vesicular chromatin, small nucleoli, and pale eosinophilic to amphophilic cytoplasm are typically observed. [1] The stroma may be myxoid or collagenous, usually containing an inflammatory infiltrate dominated by lymphocytes and plasma cells, with fewer eosinophils and neutrophils. Some tumours exhibit a compact, fascicular architecture with minimal stroma. A subset of tumour cells may resemble ganglion cells. Mitotic activity is low and necrosis is usually absent.

Immunophenotype

Essential and desirable diagnostic criteria include loose fascicles of plump spindle cells without substantial atypia or pleomorphism; inflammatory infiltrate of lymphocytes and plasma cells; consistent SMA expression; frequent ALK expression.

Finding Marker
Positive (universal) SMA
Positive (subset) desmin, ALK (~60%),[11][12] ROS1 (~5%)[13] [14]
Negative (universal) keratin
Negative (subset) CD34, S100, SOX10, and EMA

Chromosomal Rearrangements (Gene Fusions)

Confirmation of ALK or other gene rearrangements supports the diagnosis. However, molecular confirmation is not required if ALK immunohistochemistry is definitively positive.[15] Of note, exceptional situations such as inversion of ALK on the same chromosome arm may lead to a false-negative FISH result. [16], and other molecular testing such as RNA-Seq can be used to detect ALK fusions efficiently. In ALK-negative cases, immunohistochemistry for ROS1 and/or molecular tests for non-ALK gene fusions (e.g. NTRK3) may be useful.[17][18][19][14]

Chromosomal Rearrangement Genes in Fusion (5’ or 3’ Segments) Pathogenic Derivative Prevalence Diagnostic Significance (Yes, No or Unknown) Prognostic Significance (Yes, No or Unknown) Therapeutic Significance (Yes, No or Unknown) Notes
t(2;var)(p23;var) 5'var::3'ALK

(various 5’partner genes include TPM3, TPM4, CLTC, CARS, ATIC, SEC31L1, PPFIBP1, DCTN1, EML4, PRKAR1A, LMNA, TFG, FN1, HNRNPA1, etc)

der(var) 50-60%[20][21][22][23][24][25][26][27][18] Yes Yes (ALK-negative IMTs may have a higher likelihood of metastasis) Yes IMT with ALK genomic rearrangement features activation and overexpression of the ALK C-terminal kinase region, which is restricted to the neoplastic myofibroblastic component [20][15][11]
t(3;6)(q12.2;q22.1), t(6;17)(q22.1;p13.3) TFG::ROS1, YWHAE::ROS1 der(var) 5-10%[18][13][19][14][17] Yes No Yes
t(12;15)(p13.2;q25.3) ETV6::NTRK3 der(15) >5%[18][14] Yes No Yes Therapy options for NTRK fusions include Larotrectinib and Entrectinib (clinically approved)
t(5;12)(q32;q13.3) NAB2::PDGFRB der(5) >1%[18] Unknown No Yes
rea(10q11.21) rea(RET) der(10) >1%[14] Unknown No Yes Detected by FISH break-apart probe

Individual Region Genomic Gain / Loss / LOH

NA

Chr # Gain / Loss / Amp / LOH Minimal Region Genomic Coordinates [Genome Build] Minimal Region Cytoband Diagnostic Significance (Yes, No or Unknown) Prognostic Significance (Yes, No or Unknown) Therapeutic Significance (Yes, No or Unknown) Notes
NA NA
NA NA .

Characteristic Chromosomal Patterns

NA

Chromosomal Pattern Diagnostic Significance (Yes, No or Unknown) Prognostic Significance (Yes, No or Unknown) Therapeutic Significance (Yes, No or Unknown) Notes
NA

Gene Mutations (SNV / INDEL)

NA

Gene; Genetic Alteration Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other) Prevalence (COSMIC / TCGA / Other) Concomitant Mutations Mutually Exclusive Mutations Diagnostic Significance (Yes, No or Unknown) Prognostic Significance (Yes, No or Unknown) Therapeutic Significance (Yes, No or Unknown) Notes
NA

Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.

Epigenomic Alterations

NA

Genes and Main Pathways Involved

IMTs are genetically heterogeneous. About two thirds of inflammatory myofibroblastic tumours harbour receptor tyrosine kinase gene rearrangements, most often involving the ALK locus at 2p23, with diverse fusion partners. [28] Approximately 5% of inflammatory myofibroblastic tumours harbour ROS1 gene fusions; other rare gene fusions involve NTRK3, PDGFRB, and RET. [18][14][17][19][12]

Gene; Genetic Alteration Pathway Pathophysiologic Outcome
ALK fusion; activating rearrangement Kinase fusions, receptor tyrosine kinase/growth factor signaling uncontrolled cell proliferation and survival
ROS1 fusion; activating rearrangement Kinase fusions, receptor tyrosine kinase/growth factor signaling cell growth and differentiation
NTRK3 fusion; activating rearrangement Kinase fusions, receptor tyrosine kinase/growth factor signaling cell differentiation
PDGFRB fusion; activating rearrangement Kinase fusions, receptor tyrosine kinase/growth factor signaling cell growth
RET fusion; activating rearrangement Kinase fusions, receptor tyrosine kinase/growth factor signaling cell growth

Genetic Diagnostic Testing Methods

FISH, RT-PCR, RNA-seq

Familial Forms


Additional Information


Links


References

(use the "Cite" icon at the top of the page) (Instructions: Add each reference into the text above by clicking on where you want to insert the reference, selecting the “Cite” icon at the top of the page, and using the “Automatic” tab option to search such as by PMID to select the reference to insert. The reference list in this section will be automatically generated and sorted. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference.)

  1. ↑ 1.0 1.1 1.2 1.3 Coffin, C. M.; et al. (1995-08). "Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases". The American Journal of Surgical Pathology. 19 (8): 859–872. doi:10.1097/00000478-199508000-00001. ISSN 0147-5185. PMID 7611533. Check date values in: |date= (help)
  2. ↑ Makhlouf, Hala R.; et al. (2002-03). "Inflammatory myofibroblastic tumors (inflammatory pseudotumors) of the gastrointestinal tract: how closely are they related to inflammatory fibroid polyps?". Human Pathology. 33 (3): 307–315. doi:10.1053/hupa.2002.32213. ISSN 0046-8177. PMID 11979371. Check date values in: |date= (help)
  3. ↑ Khanafshar, Elham; et al. (2005-06). "Inflammatory myofibroblastic tumor of the breast". Annals of Diagnostic Pathology. 9 (3): 123–129. doi:10.1016/j.anndiagpath.2005.02.001. ISSN 1092-9134. PMID 15944952. Check date values in: |date= (help)
  4. ↑ Haj, Mahmoud; et al. (2003). "Inflammatory pseudotumor of the breast: case report and literature review". The Breast Journal. 9 (5): 423–425. doi:10.1046/j.1524-4741.2003.09516.x. ISSN 1075-122X. PMID 12968967.
  5. ↑ Zhao, Hua-Dong; et al. (2013-01). "Primary inflammatory myofibroblastic tumor of the breast with rapid recurrence and metastasis: A case report". Oncology Letters. 5 (1): 97–100. doi:10.3892/ol.2012.948. ISSN 1792-1074. PMC 3525499. PMID 23255901. Check date values in: |date= (help)
  6. ↑ Kovács, Anikó; et al. (2015). "ALK-Positive Inflammatory Myofibroblastic Tumor of the Nipple During Pregnancy-An Unusual Presentation of a Rare Disease". The Breast Journal. 21 (3): 297–302. doi:10.1111/tbj.12404. ISSN 1524-4741. PMID 25772857.
  7. ↑ 7.0 7.1 Gleason, B. C.; et al. (2008-04). "Inflammatory myofibroblastic tumours: where are we now?". Journal of Clinical Pathology. 61 (4): 428–437. doi:10.1136/jcp.2007.049387. ISSN 1472-4146. PMID 17938159. Check date values in: |date= (help)
  8. ↑ Karnak, I.; et al. (2001-06). "Inflammatory myofibroblastic tumor in children: diagnosis and treatment". Journal of Pediatric Surgery. 36 (6): 908–912. doi:10.1053/jpsu.2001.23970. ISSN 0022-3468. PMID 11381424. Check date values in: |date= (help)
  9. ↑ Tsuzuki, Toyonori; et al. (2004-12). "ALK-1 expression in inflammatory myofibroblastic tumor of the urinary bladder". The American Journal of Surgical Pathology. 28 (12): 1609–1614. doi:10.1097/00000478-200412000-00009. ISSN 0147-5185. PMID 15577680. Check date values in: |date= (help)
  10. ↑ Ramachandra, S.; et al. (1995-10). "Inflammatory pseudotumour of soft tissues: a clinicopathological and immunohistochemical analysis of 18 cases". Histopathology. 27 (4): 313–323. doi:10.1111/j.1365-2559.1995.tb01521.x. ISSN 0309-0167. PMID 8847061. Check date values in: |date= (help)
  11. ↑ 11.0 11.1 Cook, J. R.; et al. (2001-11). "Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study". The American Journal of Surgical Pathology. 25 (11): 1364–1371. doi:10.1097/00000478-200111000-00003. ISSN 0147-5185. PMID 11684952. Check date values in: |date= (help)
  12. ↑ 12.0 12.1 Pickett, Justine L.; et al. (2017-10). "Inflammatory Myofibroblastic Tumors of the Female Genital Tract Are Under-recognized: A Low Threshold for ALK Immunohistochemistry Is Required". The American Journal of Surgical Pathology. 41 (10): 1433–1442. doi:10.1097/PAS.0000000000000909. ISSN 1532-0979. PMC 5598906. PMID 28731868. Check date values in: |date= (help)
  13. ↑ 13.0 13.1 Hornick, Jason L.; et al. (2015-05). "Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors". Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc. 28 (5): 732–739. doi:10.1038/modpathol.2014.165. ISSN 1530-0285. PMC 5874150. PMID 25612511. Check date values in: |date= (help)
  14. ↑ 14.0 14.1 14.2 14.3 14.4 14.5 Antonescu, Cristina R.; et al. (2015-07). "Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement". The American Journal of Surgical Pathology. 39 (7): 957–967. doi:10.1097/PAS.0000000000000404. ISSN 1532-0979. PMC 4465992. PMID 25723109. Check date values in: |date= (help)
  15. ↑ 15.0 15.1 Coffin, C. M.; et al. (2001-06). "ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor". Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc. 14 (6): 569–576. doi:10.1038/modpathol.3880352. ISSN 0893-3952. PMID 11406658. Check date values in: |date= (help)
  16. ↑ Haimes, Josh D.; et al. (2017-06). "Uterine Inflammatory Myofibroblastic Tumors Frequently Harbor ALK Fusions With IGFBP5 and THBS1". The American Journal of Surgical Pathology. 41 (6): 773–780. doi:10.1097/PAS.0000000000000801. ISSN 1532-0979. PMID 28490045. Check date values in: |date= (help)
  17. ↑ 17.0 17.1 17.2 Yamamoto, Hidetaka; et al. (2016-07). "ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours". Histopathology. 69 (1): 72–83. doi:10.1111/his.12910. ISSN 1365-2559. PMID 26647767. Check date values in: |date= (help)
  18. ↑ 18.0 18.1 18.2 18.3 18.4 18.5 Lovly, Christine M.; et al. (2014-08). "Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions". Cancer Discovery. 4 (8): 889–895. doi:10.1158/2159-8290.CD-14-0377. ISSN 2159-8290. PMC 4125481. PMID 24875859. Check date values in: |date= (help)
  19. ↑ 19.0 19.1 19.2 Alassiri, Ali H.; et al. (2016-08). "ETV6-NTRK3 Is Expressed in a Subset of ALK-Negative Inflammatory Myofibroblastic Tumors". The American Journal of Surgical Pathology. 40 (8): 1051–1061. doi:10.1097/PAS.0000000000000677. ISSN 1532-0979. PMID 27259007. Check date values in: |date= (help)
  20. ↑ 20.0 20.1 Bridge, J. A.; et al. (2001-08). "Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor". The American Journal of Pathology. 159 (2): 411–415. doi:10.1016/S0002-9440(10)61711-7. ISSN 0002-9440. PMC 1850566. PMID 11485898. Check date values in: |date= (help)
  21. ↑ Chen, Sung-Ting; et al. (2008-12). "An inflammatory myofibroblastic tumor in liver with ALK and RANBP2 gene rearrangement: combination of distinct morphologic, immunohistochemical, and genetic features". Human Pathology. 39 (12): 1854–1858. doi:10.1016/j.humpath.2008.04.016. ISSN 1532-8392. PMID 18701132. Check date values in: |date= (help)
  22. ↑ Debelenko, Larisa V.; et al. (2003-09). "Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor". Laboratory Investigation; a Journal of Technical Methods and Pathology. 83 (9): 1255–1265. doi:10.1097/01.lab.0000088856.49388.ea. ISSN 0023-6837. PMID 13679433. Check date values in: |date= (help)
  23. ↑ Griffin, C. A.; et al. (1999-06-15). "Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors". Cancer Research. 59 (12): 2776–2780. ISSN 0008-5472. PMID 10383129.
  24. ↑ Lawrence, B.; et al. (2000-08). "TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors". The American Journal of Pathology. 157 (2): 377–384. doi:10.1016/S0002-9440(10)64550-6. ISSN 0002-9440. PMC 1850130. PMID 10934142. Check date values in: |date= (help)
  25. ↑ Takeuchi, Kengo; et al. (2011-05-15). "Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK: reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification". Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 17 (10): 3341–3348. doi:10.1158/1078-0432.CCR-11-0063. ISSN 1557-3265. PMID 21430068.
  26. ↑ Yamamoto, Hidetaka; et al. (2006-10). "Absence of human herpesvirus-8 and Epstein-Barr virus in inflammatory myofibroblastic tumor with anaplastic large cell lymphoma kinase fusion gene". Pathology International. 56 (10): 584–590. doi:10.1111/j.1440-1827.2006.02012.x. ISSN 1320-5463. PMID 16984614. Check date values in: |date= (help)
  27. ↑ Inamura, Kentaro; et al. (2017-11). "A novel fusion of HNRNPA1-ALK in inflammatory myofibroblastic tumor of urinary bladder". Human Pathology. 69: 96–100. doi:10.1016/j.humpath.2017.04.022. ISSN 1532-8392. PMID 28504207. Check date values in: |date= (help)
  28. ↑ Mariño-Enríquez, Adrian; et al. (2013-11). "ALK as a paradigm of oncogenic promiscuity: different mechanisms of activation and different fusion partners drive tumors of different lineages". Cancer Genetics. 206 (11): 357–373. doi:10.1016/j.cancergen.2013.07.001. ISSN 2210-7762. PMID 24091028. Check date values in: |date= (help)

EXAMPLE Book

  1. Arber DA, et al., (2017). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p129-171.

Notes

*Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage).  Additional global feedback or concerns are also welcome.

Retrieved from "https://ccga.io/index.php?title=BRST5:Inflammatory_myofibroblastic_tumour&oldid=13453"